Live Breaking News & Updates on Phase 3 trials

Stay informed with the latest breaking news from Phase 3 trials on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Phase 3 trials and stay connected to the pulse of your community

Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab for Treating COPD, Type 2 Inflammation

Patients with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation had significantly better lung function at least a year into a dupilumab regimen.

Ivelin-radkov , Naimish-patel , Georged-yancopoulos , European-medicines-agency , Global-development , Copd- , Phase-3-trials , Dupilumab , Type-2-inflammation ,

Inclusion of 65+ age in JE vax trial urged

The plan is to develop an advanced version of JE vaccine that can cover a larger chunk of the population.

China , Telangana , Andhra-pradesh , India , Odisha , Orissa , Chhattisgarh , Pune , Maharashtra , Japan , Karnataka , Bharat

Dogs can get a Lyme disease vaccine. Why can′t we? | Science | In-depth reporting on science and technology | DW

Ever met a dog that's anti-vax? Probably not. And that's why they can be protected from dangerous tick bites, but we can't (yet).

Lyme-disease , Borrelia-burgdorferi , Ticks , Bacteria , Joint-pain , Memory-problems , Fatigue , Tiredness , Headaches , Neck-stiffness , Heart-palpitations

Ocugen Files Application with FDA to Conduct Phase 3 Trials of Covaxin in the US

Ocugen, which is partnering with Bharat Biotech to develop Covaxin for the US market, said on Wednesday, 27 October that it has submitted an Investigational New Drug Application to the US Food and Drug Administration to conduct clinical trials.

United-states , India , American , Bharat , Drug-administration , Bharat-biotech , Investigational-new-drug-application , Ocugen , Covaxin , Fda , Us-fda

Centre reserves 30 crore doses of Biological E's Covid-19 vaccine with an advance payment of ₹1,500 crore

The vaccine candidate is undergoing phase 3 trials now

Faridabad , Haryana , India , Indian-covid , Research-institute-translational-health-science-technology , Union-ministry-of-health , Vaccine-development-mission , Government-of-india-mission-covid-suraksha , Research-development , Department-of-biotechnology , Union-ministry , National-expert-group

The Problems With One-Dose Covishield

The Problems With One-Dose Covishield
If Covishield is administered as a single-dose vaccine, a small study found its efficacy against symptomatic COVID-19 caused by the B.1.617.2 variant is only 33%.
Photo: Artem Podrez/Pexels
Health4 hours ago
On May 31, NDTV quoted unnamed sources in the Indian government saying it will be conducting a study to assess the feasibility of deploying the Covishield vaccine in a single-dose regimen instead of continuing the extant double-dose regimen.
At any other time, such a statement may have been sufficient to believe the government would organise and conduct a well-designed trial, publicise the findings and revise policy (or not) to stay in line with the findings, informed by socio-economic considerations. But the last 15 months have thrown up enough incidents of public-health malpractice on the state’s part to make such hope foolish. There is a nontrivial chance, especially if the vaccine shortage persists and the outbreaks on an upward trajectory in some parts of the country at the moment aren’t tamped down quickly, that the government is going to conduct a trial, not publish its methods and findings and push through a policy to deploy Covishield as a single-dose shot.

India , Chennai , Tamil-nadu , Bharat , Pfizer , National-institute-of-epidemiology , Astrazeneca , University-of-oxford , Public-health-england , Serum-institute , National-institute

Covid treatment: Optimus Pharma gets DCGI nod for phase 3 trials of Molnupiravir

May 19, 2021
The orally administered drug is being tested for treating mild and moderate infection
Optimus Pharma has received the approval of the Drug Controller General of India (DCGI) to conduct Phase III clinical trials of orally administered Molnupiravir capsules on patients with mild and moderate Covid-19 infection.
As per the clinical trial protocols approved, a total of 2,500 subjects in both mild and moderate Covid-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care.
Treatment modes
The treatment duration is a maximum of five days and the total study duration will be maximum for 29 days from randomisation, the Hyderabad-based company said in a release on Wednesday.

Hyderabad , Andhra-pradesh , India , D-srinivas-reddy , Optimus-pharma , Drug-controller-general , Srinivas-reddy , Managing-director , Covid-19 , Corona , Pandemic

Oxygen Concentrator Banks to be set up across Delhi: CM Arvind Kejriwal

Delhi Chief Minister Arvind Kejriwal. Photo: Twitter/@ArvindKejriwal

Delhi Chief Minister Arvind Kejriwal on May 15 announced the setting up of Oxygen Concentrator Banks across the city to aid patients in home isolation as well as for recovery after being discharged from the hospital.
He also said that both the COVID-19 cases as well as the positivity rate were declining steadily across the city, but reiterated that citizens should not let their guard down.
“Around 6,000 COVID cases have emerged in the last 24 hours and the positivity rate has gone down to 11%, which is a sign that things are constantly improving,” Mr. Kejriwal said in a video message.

Delhi , India , Delhi-chief-minister-arvind-kejriwal , Oxygen-concentrator-banks , Chief-minister , Arvind-kejriwal , Corona-virus , Covishield , Covaxin , Remdesivir , Tocilizumab

Coronavirus | Lockdown to become more intense in Kerala from May 17

Coronavirus | Lockdown to become more intense in Kerala from May 17
Updated:
Updated:
Four districts to be under triple lockdown
Share Article
AAA
Police personnel check vehicles at IMA junction in Palakkad, Kerala on May 15, 2021. | Photo Credit:
K.K. Mustafah
Four districts to be under triple lockdown
Kerala will move into a highly restrictive lockdown phase on May 17. The government will review the regulations again on May 23. A senior official said any relaxation is unlikely till the surge in COVID-19 infections abated to an acceptable level.
Chief Secretary V. P. Joy is chairing a series of meetings and Chief Minister Pinarayi Vijayan is likely to make an announcement around 6 p.m.

Thiruvananthapuram , Kerala , India , Thrissur , Malappuram , Andaman-and-nicobar-islands , Ernakulam , Pinarayi-vijayan , Chief-minister-pinarayi-vijayan , Vp-joy , Corona-virus

PM Modi speaks to CMs of four States on COVID situation

PM Modi speaks to CMs of four States on COVID situation
Updated:
Updated:
May 09, 2021 13:43 IST
PM Modi has been speaking to State Chief Ministers and Lieutenant Governors of Union Territories to asses the pandemic situation there and offer suggestions
Share Article
Prime Minister Narendra Modi. File photo: YouTube/Bharatiya Janata Party

PM Modi has been speaking to State Chief Ministers and Lieutenant Governors of Union Territories to asses the pandemic situation there and offer suggestions
Prime Minister Narendra Modi on May 9 spoke to the Chief Ministers of Punjab, Karnataka, Bihar and Uttarakhand on the COVID-19 situation in their States, official sources said.

India , Karnataka , Uttarakhand , Uttaranchal , Bihar , Lieutenant-governors-of-union-territories , Union-health-ministry , Prime-minister-narendra-modi , Chief-ministers , State-chief-ministers , Lieutenant-governors